-
1 Comment
Kangmei Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 14.4% above its 200 day moving average.
From a valuation standpoint, the stock is 77.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Kangmei Pharmaceutical Co., Ltd's total revenue sank by 34.3% to $1B since the same quarter in the previous year.
Its net income has dropped by 1711.1% to $-948M since the same quarter in the previous year.
Finally, its free cash flow fell by 57.9% to $420M since the same quarter in the previous year.
Based on the above factors, Kangmei Pharmaceutical Co., Ltd gets an overall score of 2/5.
| CurrencyCode | CNY |
|---|---|
| ISIN | CNE0000017M1 |
| Exchange | SHG |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector | Healthcare |
| Dividend Yield | 0.0% |
|---|---|
| Market Cap | 30B |
| Beta | 0.71 |
| Target Price | 27.25 |
| PE Ratio | 3.61 |
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese medicines in China. It also offers chemical drug products; and operates hospitals and Chinese medicine pharmacies. The company was founded in 1997 and is headquartered in Puning, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600518.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
